European Commission Greenlight for Zynyz Marks Major Therapeutic Milestone in Advanced Anal Cancer Treatment

The European Commission has officially greenlit Zynyz (retifanlimab) as a first-line combination therapy for patients with metastatic or surgically unresectable locally recurrent squamous cell carcinoma of the anal canal (SCAC). This regulatory decision represents a significant therapeutic advance, building on the positive recommendation issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use in January 2026. The approval designation positions this as the second major indication for Zynyz within the EU, expanding treatment options in oncology.

Clinical Evidence Supporting Anal Cancer Indication

The regulatory clearance is anchored in robust clinical trial data from the Phase 3 POD1UM-303/InterAACT2 trial, which evaluated the efficacy and safety of retifanlimab combined with the standard platinum-based chemotherapy regimen (carboplatin and paclitaxel). The trial enrolled adult patients with metastatic or locally advanced anal squamous cell carcinoma who had not previously received systemic chemotherapy, representing a treatment-naïve population. These patients represent an important demographic in need of improved therapeutic options, as anal cancer incidence has shown concerning trends in recent years.

Broader Therapeutic Portfolio and Market Impact

Prior to this anal cancer approval, Zynyz already demonstrated clinical efficacy as monotherapy for treating Merkel cell carcinoma (MCC), securing approvals across multiple major markets including the United States, European Union, Canada, and Switzerland. This multi-indication approval strategy reflects the broad potential of retifanlimab across different cancer types. Incyte, which holds exclusive global rights to retifanlimab through its long-standing collaboration with MacroGenics Inc. dating to 2017, continues to expand the drug’s accessibility and clinical applications. The marketing authorization in Europe builds on the existing U.S. approval, creating a cohesive global treatment framework for patients requiring first-line immunotherapy-chemotherapy combinations.

Clinical Significance and Patient Perspectives

For patients diagnosed with advanced anal squamous cell carcinoma, this approval provides a validated first-line treatment option combining immunotherapy with conventional chemotherapy—addressing a therapeutic gap in this patient population. The approval underscores the evolving treatment landscape where combination approaches, particularly those pairing immune checkpoint inhibitors with platinum-based agents, are becoming standard-of-care interventions across multiple cancer indications.